上諭集團(01633.HK)中期純利升16.6%至628.7萬港元 在手合同3.29億港元
格隆匯11月22日丨上諭集團(01633.HK)公佈截至2022年9月30日止6個月的中期業績,期內公司實現收入1.50億港元,同比增長32.4%;毛利2173.6萬港元,同比增長36.0%;公司擁有人應占期內盈利628.7萬港元,同比增長16.6%;每股基本盈利0.92港仙,不派中期股息。
截止2022年9月30日,集團手頭有8個項目,總合約金額約為3.29億港元,其中6個項目預期將於下個財政年度完成。於該期間結束後,集團獲授予兩個地基工程項目,其合約金額約為1.49億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.